As mentioned, assessing the levels of ACE2 and TMPRSS2 species in the plasma of IBD patients could be potentially informative to gain a more systemic perspective on their potential vulnerability to COVID-19. This evidence concerns the gene ACE2 and inflammatory bowel disease.